Biblio

Export 71 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229PDF icon Marc Achen et al., PNAS 1998 (447.59 KB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Anisimov A, Leppänen V-M, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, et al.. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. PDF icon Anisimov 2013 Science Signaling (1.92 MB)PDF icon Anisimov 2013 Science Signaling Supplement (2.09 MB)
Anisimov A, Tvorogov D, Alitalo A, Leppänen V-M, An Y, Han EC, et al.. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. PDF icon Anisimov 2013 (6.56 MB)PDF icon Anisimov 2013 Supplement (4.93 MB)
Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, et al.. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res [Internet]. 2009;104(11):1302 - 12. http://view.ncbi.nlm.nih.gov/pubmed/19443835PDF icon Andrey Anisimov et al., Circulation Research 2009 (8.03 MB)PDF icon Andrey Anisimov et al., Circulation Research 2009, supplement (5.9 MB)
B
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734PDF icon Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Batchu KChaithanya, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-β-mediated glycerophospholipid hydrolysised. Journal of Biological Chemistry [Internet]. 2015;. http://www.jbc.org/content/early/2015/02/23/jbc.M115.642835.abstractPDF icon J. Biol. Chem.-2015-Batchu-jbc.M115.642835.pdf (786.13 KB)
Batchu KChaithanya, Hänninen S, Jha SKumar, Jeltsch M, Somerharju P. Factors regulating the substrate specificity of cytosolic phospholipase A2-alpha in vitro. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2016;1861(11):1597. PDF icon Batchu et al. - 2016 - Factors regulating the substrate specificity of cy.pdf (986.25 KB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)
C
Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, et al.. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem [Internet]. 1997;272(40):25176 - 83. http://view.ncbi.nlm.nih.gov/pubmed/9312130PDF icon Dmitry Chilov et al., The Journal of Biological Chemistry 1997  (517.68 KB)
D
Dashkevich A, Raissadati A, Syrjälä SO, Zarkada G, Keränen MAI, Tuuminen R, et al.. Ischemia-Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts. American Journal of Transplantation [Internet]. 2015;16(4):1160-1172. http://onlinelibrary.wiley.com/doi/10.1111/ajt.13564/abstract
E
Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, et al.. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res [Internet]. 2001;88(6):623 - 9. http://view.ncbi.nlm.nih.gov/pubmed/11282897PDF icon Bernd Enholm et al., Circulation Research 2001 (2.93 MB)
F
Fang S, Chen S, Nurmi H, Leppänen V-M, Jeltsch M, Scadden DT, et al.. VEGF-C Protects the Integrity of Bone Marrow Perivascular Niche. Blood [Internet]. 2020;:accepted - for publication. https://ashpublications.org/blood/article/doi/10.1182/blood.2020005699/463465/VEGF-C-Protects-the-Integrity-of-Bone-MarrowPDF icon Fang et al. 2020 - VEGF-C protects the integrity of bone marrow perivascular niche (6 MB)
G
Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al.. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol [Internet]. 2003;161(6):1163 - 77. http://view.ncbi.nlm.nih.gov/pubmed/12810700PDF icon Holger Gerhardt et al., The Journal of Biological Chemistry 2003 (2.24 MB)
Gucciardo E, Lehti TA, Korhonen A, Salvén P, Lehti K, Jeltsch M, et al.. Lymphatics and the eye. [Finnish]. Duodecim Lääketieteellinen Aikakauskirja [Internet]. 2020;136(16):1777-1788. https://www.duodecimlehti.fi/lehti/2020/16/duo15739PDF icon Gucciardo et al. Lymphatics and the Eye (English version). (3.31 MB)
H
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF icon Yulong He et al., Cancer Research 2005 (1.82 MB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, et al.. Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809PDF icon Heckman et al. - 2007 - Inhibiton of VEGF-C-induced VEGFR-3 activity and l.pdf (236.37 KB)
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103PDF icon Mikko Hiltunen et al., Circulation 2000 (1.44 MB)
J
Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem [Internet]. 2006;281(17):12187 - 95. http://view.ncbi.nlm.nih.gov/pubmed/16505489PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006 (1.04 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 1 (1.01 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 2 (596.06 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 3 (738.98 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 4 (710.03 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 5 (163.64 KB)
Jeltsch M. Lymphangiogenesis in Health and Disease [Internet]. 41st European Societry of Lymphology (ESL) Congress. Lausanne, Switzerland: European Group of Lymphology; 2015. http://www.eurolymphology.org/JOURNAL/VOL26-N72-2015/#p=10PDF icon Abstract of the Presentation (Michael Jeltsch) (75.34 KB)
Jeltsch M. From Molecular Genetics and Biology to Effective Treatments of Lymphatic Disorders [Internet]. 42nd Congress of the European Society of Lymphology. Mulhouse, France; 2016. http://www.eurolymphology.org/JOURNAL/VOL28-N74-2016/#p=14PDF icon Jeltsch 2016: From Molecular Genetics and Biology to Effective Treatments of Lymphatic Disorders (683.85 KB)
Jeltsch M. What you should know about VEGF-C when working with lymphatics [German]. In Lymphologie 2017 [Internet]. Bad Soden (Frankfurt), Germany; 2017. https://jeltsch.org/Abstrakt-BadSoden2017PDF icon Extended Abstract (published in Vasomed, 2018) (226.5 KB)
Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res [Internet]. 2003;314(1):69 - 84. http://view.ncbi.nlm.nih.gov/pubmed/12942362PDF icon Michael Jeltsch et al., Cell and Tissue Research 2003 (562.33 KB)
Jeltsch M, Alitalo K. VEGF Receptors. In Sigma-RBI Handbook of Receptor Classification and Signal Transduction [Internet]. 5.th ed. Sigma; 2006. http://www.sigmaaldrich.com/technical-documents/articles/biology/rbi-handbook.htmlPDF icon Sigma-RBI Handbook of Receptor Classification and Signal Transduction: VEGF Receptors (263.92 KB)

Pages